Antidepressant Medication Articles & Analysis: Older
3 news found
The trial, MOOD, will assess the safety and efficacy of Relivion DP as an adjunctive treatment to pharmaceutical management of MDD in adults who have not achieved satisfactory improvement from antidepressant medications. The first patient was enrolled at Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, RI. “With ...
Treatment of PPD is centred around psychotherapy and/or antidepressant medication. Postpartum psychosis This is the most severe form of postpartum psychiatric illness. ...
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. A wearable device, the Relivion®DP system is designed as an adjunctive treatment ...